India’s interim budget 2024 hikes allocation for production-linked incentive schemes in pharmaceuticals, supports biotech start-ups - particularly green ones- and sets the right note for inclusion of HPV vaccination in the country’s Universal Immunization Program, one of the world's largest public health programs. How does it help?

With an ambitious growth plan for its CDMO operations, Ajinomoto is planning to complete the acquisition of Forge Biologics Holdings by December, adding the US-based firm’s capabilities in gene therapy services.

Scrip delves into some of India’s critical compliance and quality challenges and efforts to address those. 

A year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir, we look at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023, as Hetero’s version becomes the first with WHO prequalification while two Chinese and a Korean company wait in the wings.